Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
about
Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trialStatins for multiple sclerosisImportance of Apolipoprotein A-I in Multiple SclerosisCurrent and Emerging Uses of Statins in Clinical Therapeutics: A ReviewAberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body EcologyTherapeutic decisions in multiple sclerosis: moving beyond efficacyStatin treatment in multiple sclerosis: a systematic review and meta-analysis.Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.Modulation of dendritic cell immunobiology via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase.Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosisSimvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration.Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS studyInterference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1,25-dihydroxyvitamin D3 in experimental autoimmune encephalomyelitis.Glatiramer acetate treatment negatively regulates type I interferon signaling.Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trialCombinatorial Effect of Metformin and Lovastatin Impedes T-cell Autoimmunity and Neurodegeneration in Experimental Autoimmune Encephalomyelitis.Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins.Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review.Arterial, venous and other vascular risk factors in multiple sclerosis.Immunotherapy of multiple sclerosis: the state of the art.The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.Combining statins with interferon β in multiple sclerosis: think twice, it might not be all rightStatins: a revised appraisal for potential additional future treatment indications.Simvastatin: Multiple Sclerosis.Multiple sclerosis: combination therapy in MS--still a valid strategy.Attenuation of experimental autoimmune neuritis with locally administered lovastatin-encapsulating poly(lactic-co-glycolic) acid nanoparticles.Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis.Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)."No evidence of disease activity" - is it an appropriate surrogate in multiple sclerosis?
P2860
Q21559486-37CD648C-FE45-4094-BAE3-E4AA32D0C63CQ24234119-D9490E61-C167-4A03-9201-F32AE8743186Q26774792-2675E32A-4D1F-4A72-A114-DA83A3325C26Q28076346-5A61F7EF-ED48-49B5-98D0-B595578EB52AQ28299160-A7818B6E-65A2-417C-8318-62D5AD10ABADQ28541039-6BB46A13-B574-47A6-8B97-8E3F857571DAQ30913423-53077EEB-5296-4803-B85B-ED8C3ED4E4A1Q34109028-1EDB3019-C132-4EB3-BA97-8E112A5D24E3Q35205220-B7A9A27E-78D3-4E4E-80A8-6A3B16257385Q35586845-0182F8A1-450C-433F-94A5-C13E68303003Q35838945-51CF85D1-E023-4670-9B73-27A01AEC6199Q35872344-A2999B1C-B476-4CD5-9CD7-2DBF9F1D95DEQ36204144-20880491-860B-4213-A980-B6A20BFFEA32Q36280868-EDC40212-11FF-4006-BF06-349A212A5B39Q36357176-990A6E6D-4B7C-4BEE-9F6A-684E87120976Q37373698-0BECAC2B-69EF-4E6F-97DC-FEF5BD701C6FQ37543452-24765953-A779-433E-9A84-3F72D9126710Q37580266-A49384C8-1D4C-496B-A057-0584610089BCQ38020536-71CABA12-E56C-4950-AB88-B097E50D03E1Q38042766-628B38DA-9BFA-4B7E-8C7D-525A3F087713Q38083041-44EDF976-6EEC-4F02-8409-FB26C0A3B98FQ38761495-D0E58ED4-7AF9-49A5-93F0-1DC7BEB322C7Q38801807-49F3C73E-5F0B-4E3E-B993-63F632A51E0CQ40020998-DCDEC540-5055-4E4F-8000-78C8954A8781Q40101603-0F10DE4C-BB65-4871-9A0B-F3A89B8A9B4EQ41841667-AB11A624-E35C-48DD-A676-F6A6D522C1E0Q42326349-E7C448CD-F9E7-49A7-97E9-9CD75A08D6D6Q43225143-1575B7FF-EF29-4FD2-B720-8EE358BD06E8Q43704412-608CAF76-4086-4EE8-9E61-EF5E42A12158Q48032010-5155ECCA-3A34-4FB7-8E8F-E50026B54F56Q49139039-439CCE30-1990-47F3-94E2-E454E573C3BDQ51062974-AB8F7F29-77DC-4C3A-830D-B9CB32CBE992Q52147931-9B3BF61F-80E2-4439-88E6-7CA0EBBD6521Q52567799-B0E8D4EF-E2AA-4CF6-B6CE-6C9073A69A55
P2860
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Simvastatin as add-on therapy ...... lled randomised phase 4 trial.
@en
Simvastatin as add-on therapy ...... g-remitting multiple sclerosis
@nl
type
label
Simvastatin as add-on therapy ...... lled randomised phase 4 trial.
@en
Simvastatin as add-on therapy ...... g-remitting multiple sclerosis
@nl
prefLabel
Simvastatin as add-on therapy ...... lled randomised phase 4 trial.
@en
Simvastatin as add-on therapy ...... g-remitting multiple sclerosis
@nl
P2093
P50
P921
P1433
P1476
Simvastatin as add-on therapy ...... olled randomised phase 4 trial
@en
P2093
Annette Oturai
Astrid Edland
Egon Stenager
Helle Bach Sondergaard
Jette Lautrup Frederiksen
Juha-Pekka Erälinna
SIMCOMBIN study investigators
Xingchen Wu
P304
P356
10.1016/S1474-4422(11)70144-2
P577
2011-08-01T00:00:00Z